In waiting for a retestAre you interrested in buying NASDAQ:VRTX ? I'm looking for a break confirmation of the 2-years trendline to evaluate a first entry in the 370s. Then the POC line could be a valid support to regain the trend.
12.70EUR
3.28 BEUR
8.91 BEUR
257.54 M
About VERTEX PHARMAC. DL-,01
Sector
CEO
Reshma Kewalramani
Headquarters
Boston
Website
Employees (FY)
5.4 K
Founded
1989
ISIN
US92532F1003
FIGI
BBG000RYN8N7
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
VRTX Stock – the Alternative to OxyContin?In the wake of the opiod epidemic, brought on in part by the success of Oxycodone, a new exceptional drug is being developed by Vertex Pharmaceuticals (NASDAQ: VRTX). With the intention of providing relief from severe pain without the addictive properties of opioids, Vertex’s new drug could be on tr
temporary pain for long term gainsAs price action is currently receiving short term bearishness from sellers from being near all time highs, accumulation of shares are lessening however the uptrend has been strong overall. Look for more of a pullback leading into earnings and with strong support should provide another entry long in
Stock of the Month: Vertex (VRTX)Our portfolio is up by more than 15% in the month of November. We are strictly following Mark Minervini's Trading Methodology. Here is a quick summary:
Mark Minervini's trading methodology, often encapsulated in his SEPA (Specific Entry Point Analysis) system, is a comprehensive approach to trading
Vertex’s Stock Heads for All-Time HighVertex Pharmaceuticals Inc. shares were on track for an all-time high Wednesday after the company released new data from a trial of its investigational non-opioid pain medicine.
The stock jumped more than 10% Wednesday morning, on pace for its largest percentage gain in more than three years, and w
Vertex Pharmaceuticals: Riding the Bullish Wave with a Bull Put In the world of trading, there are a variety of strategies that investors can employ to maximize their returns. One such strategy that has gained popularity in recent years is the vertical spread bull put. This strategy involves buying a put option with a lower strike price and selling a put option
VRTX shortHi traders,
let's have a look at VRTX analysis on daily timeframe.
The support at 342$ has been retested many times however, this time we are expecting support to fail.
If horizontal support fails and the price breaks upslopping support (blue line), it will look more bearish and short position ca
Trading Idea: Buy Vertex Pharmaceuticals (VRTX) StockVertex Pharmaceuticals (VRTX) has experienced a decline of around 5.84% in its share price over the past month. However, based on the provided facts, it appears that Vertex Pharmaceuticals is in a strong financial position and could be a good investment opportunity.
Here is the core logic behind th
VRTX: opened a new 10% positionWe have added a new position and here is a link to the updated portfolio:
www.tradingview.com
VRTX had a positive earnings surprise on Nov 6th which pushed the price up to new highs. These new highs have been followed by a natural pullback which occured under low trading volume.
The new position
Vertex at its VertexThe 1-2-3-4-5 Impulse Wave (blue wave) formation on VRTX is nearly complete. We can see a rising wedge (white colour) after impulse wave 3. This is impulse wave 5, which can be in the form of a wedge. VRTX is consolidating at the top. It may make one last effort to reach the top, form a double top a
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where VX1 is featured.
Frequently Asked Questions
The current price of VX1 is 367.50 EUR — it has decreased by 0.10% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange VERTEX PHARMAC. DL-,01 stocks are traded under the ticker VX1.
VERTEX PHARMAC. DL-,01 is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
VX1 stock is 0.10% volatile and has beta coefficient of 0.94. Check out the list of the most volatile stocks — is VERTEX PHARMAC. DL-,01 there?
One year price forecast for VERTEX PHARMAC. DL-,01 has a max estimate of 540.65 EUR and a min estimate of 306.10 EUR.
VX1 earnings for the last quarter are 3.86 EUR per share, whereas the estimation was 3.72 EUR resulting in a 3.72% surprise. The estimated earnings for the next quarter are 3.68 EUR per share. See more details about VERTEX PHARMAC. DL-,01 earnings.
VERTEX PHARMAC. DL-,01 revenue for the last quarter amounts to 2.35 B EUR despite the estimated figure of 2.37 B EUR. In the next quarter revenue is expected to reach 2.28 B EUR.
Yes, you can track VERTEX PHARMAC. DL-,01 financials in yearly and quarterly reports right on TradingView.
VX1 stock has fallen by 1.53% compared to the previous week, the month change is a 2.91% fall, over the last year VERTEX PHARMAC. DL-,01 has showed a 23.12% increase.
VX1 net income for the last quarter is 877.74 M EUR, while the quarter before that showed 979.39 M EUR of net income which accounts for −10.38% change. Track more VERTEX PHARMAC. DL-,01 financial stats to get the full picture.
Today VERTEX PHARMAC. DL-,01 has the market capitalization of 95.50 B, it has decreased by 2.06% over the last week.
No, VX1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, VX1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VERTEX PHARMAC. DL-,01 stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 5.40 K employees. See our rating of the largest employees — is VERTEX PHARMAC. DL-,01 on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VERTEX PHARMAC. DL-,01 technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VERTEX PHARMAC. DL-,01 stock shows the buy signal. See more of VERTEX PHARMAC. DL-,01 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on VERTEX PHARMAC. DL-,01 future price: according to them, VX1 price has a max estimate of 540.66 EUR and a min estimate of 306.12 EUR. Read a more detailed VERTEX PHARMAC. DL-,01 forecast: see what analysts think of VERTEX PHARMAC. DL-,01 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VERTEX PHARMAC. DL-,01 EBITDA is 3.58 B EUR, and current EBITDA margin is 45.32%. See more stats in VERTEX PHARMAC. DL-,01 financial statements.